Displaying drugs 15051 - 15075 of 15881 in total
ALT-P1
ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Investigational
TRK-250
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
BJ-001
BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding motif.
Investigational
Recombinant human placental growth factor (PLGF-131)
Investigational
GYM329
GYM329 is a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH-dependent manner
Investigational
VCA-894A
VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
Investigational
MT-401
MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.
Investigational
TUM012
TUM012 is a synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)
Investigational
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
BG1805
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
Investigational
Recombinant human insulin-like growth factor 1
Investigational
Rovaleucel
Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Investigational
RCT1100
RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.
Investigational
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
Venanprubart
Venanprubart is under investigation in clinical trial NCT05781451 (Anti-btla Agonist Therapy in Subjects With Primary Sjogren's Syndrome).
Investigational
Zigakibart
Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).
Investigational
Verzistobart
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
Vamikibart
Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema).
Investigational
Narlumosbart
Narlumosbart is under investigation in clinical trial NCT06314698 (Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease).
Investigational
Insulin efsitora alfa
Insulin efsitora alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)).
Investigational
Elebsiran
Elebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).
Investigational
Bevonescein
Bevonescein is under investigation in clinical trial NCT06227585 (Feasibility Study- REVEAL 475 for Bevonescein-assisted Nerve Visualization in Head & Neck Surgery).
Investigational
Yttrium Y-90 epratuzumab tetraxetan
Investigational
Displaying drugs 15051 - 15075 of 15881 in total